VWF, von Willebrand factor, 7450

N. diseases: 498; N. variants: 158
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Purpura, Thrombotic Thrombocytopenic
0.100 AlteredExpression disease BEFREE The regulation of VWF multimer size is essential in preventing spontaneous microvascular platelet clumping, a central pathophysiologic finding in thrombotic thrombocytopenic purpura (TTP). 23233642 2012
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE Thrombotic thrombocytopenic purpura (TTP) is a disorder with characteristic von Willebrand factor (VWF)-rich microthrombi affecting the arterioles and capillaries of multiple organs. 20058209 2010
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Histone-induced thrombotic thrombocytopenic purpura in adamts13-/- zebrafish depends on von Willebrand factor. 31753928 2019
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The presence of unusually large multimers of von Willebrand factor (VWF) is thought to be a major pathogenic factor for thrombotic thrombocytopenic purpura (TTP). 15662617 2005
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE We conducted this study to examine if vWF is involved in the increased platelet retention in TTP. 9423794 1997
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE Recent studies have found autoimmune inhibitors or genetic mutations of a von Willebrand factor (VWF) cleaving metalloprotease ADAMTS13 in patients with TTP. 16760911 2006
Purpura, Thrombotic Thrombocytopenic
0.100 AlteredExpression disease BEFREE Despite a clinical diagnosis of TTP, the patient had normal ADAMTS-13 levels and increased VWF antigen levels with ultra-large von Willebrand factor multimers. 26613809 2016
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severely deficient activity of the von Willebrand Factor (VWF) cleaving metalloprotease, ADAMTS13, is associated with thrombotic thrombocytopenic purpura (TTP). 16807643 2006
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Force-regulated cleavage of A2 domain of von Willebrand factor (vWF) by ADAMTS13 is a key event in preventing thrombotic thrombocytopenic purpura (TTP). 29636514 2018
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Thrombotic thrombocytopenic purpura (TTP) is associated with congenital and acquired deficiency of ADAMTS-13, a metalloprotease that cleaves von Willebrand factor (VWF) and reduces its adhesive activity. 16796708 2006
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The identification of antibodies against a plasma metalloproteinase responsible for cleaving ultralarge von Willebrand factor multimers in thrombotic thrombocytopenic purpura has been followed by the elucidation of the identity of the proteinase. 12105394 2002
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE <i>N</i>-acetylcysteine (NAC), an FDA-approved anti-mucolytic agent, is a possible new treatment strategy for TTP, as it was demonstrated to reduce disulfide bonds in VWF, thereby decreasing VWF multimers size and hence their prothrombotic potential. 28011677 2017
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severe deficiency of von Willebrand factor (VWF)-cleaving protease (ADAMTS-13) activity (<5% of normal) is a specific finding for acute idiopathic thrombotic thrombocytopenic purpura (TTP), a disorder that presents as thrombocytopenia, microangiopathic hemolytic anemia, and often organ dysfunction such as neurological disturbances or renal failure, and fever. 14727262 2004
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Acquired thrombotic thrombocytopenic purpura (TTP) is a potentially fatal disease in which ultralarge von Willebrand factor (UL-VWF) multimers accumulate as a result of autoantibody inhibition of the VWF protease, ADAMTS13. 27040023 2016
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Recent studies demonstrate that assay of ADAMTS13, a circulating zinc metalloprotease that cleaves von Willebrand factor (VWF) at the Y1605-M1606 bond, is an important tool in the diagnosis of thrombotic thrombocytopenic purpura (TTP). 15045144 2004
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE The congenital or acquired deficiency of the von Willebrand factor (VWF) cleaving protease, ADAMTS-13 has been specifically associated with a diagnosis of thrombotic thrombocytopenic purpura (TTP), a microangiopathy characterized by the formation of occlusive platelet thrombi. 15521921 2004
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE Hereditary thrombotic thrombocytopenic purpura is caused by mutations in a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS13) resulting in defective processing of von Willebrand factor (VWF) that causes intravascular platelet aggregation culminating in thrombocytopenia with shistocytic anemia. 19786614 2009
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severe deficiency of ADAMTS13, a von Willebrand factor (VWF)-cleaving metalloprotease, causes thrombotic thrombocytopenic purpura. 17426255 2007
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE In TTP thrombi formation occurs subsequently to the release of multimers of von Willebrand Factor (vWF) and in HUS (both typical and atypical) to endothelial cell damage (via toxins or complement dysregulation). 19640589 2009
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE As the anchored VWF chains grow, they provide a greater surface area to bind circulating platelets (PLTs), generating unique thrombi that characterize TTP. 30208220 2018
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE ADAMTS13 and von Willebrand factor (VWF) are closely related to the onset of TTP. 26759371 2017
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE In some variants of type 2A vWF, the cleavage site in the vWF subunit is more susceptible to proteolytic degradation than in normal vWF, whereas in patients with TTP or HUS the protease activity may be suppressed. vWF-degrading protease plays an important role in pathogenesis of congenital or acquired disorders of hemostasis and thrombosis. 8767102 1996
Purpura, Thrombotic Thrombocytopenic
0.100 AlteredExpression disease BEFREE We investigated whether VWF-HMWM level at acute phase of TTP could be a predictive factor for morbidity. 31330376 2019
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE Finally, (4) studies of patients with primary disorders of excess or deficiency of function in the vWF axis (e.g. thrombotic thrombocytopenic purpura and von Willebrand disease, respectively) which demonstrate the crucial role of vWF in atherothrombosis. 29847840 2018
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Failure to degrade "unusually large" (UL) von Willebrand factor (VWF) multimers as they are secreted from endothelial cells probably causes most cases of familial TTP, acquired idiopathic TTP, thienopyridine-related TTP, and pregnancy-associated TTP. 14727254 2004